OPKO Health (OPK) Tops Q4 EPS by 3c, provides guidance

OPKO Health (NASDAQ: OPK) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $148.5 million versus the consensus estimate of $139.76 million.

GUIDANCE:

OPKO Health sees Q1 2026 revenue of $125-140 million, versus the consensus of $130.8 million.

For earnings history and earnings-related data on OPKO Health (OPK) click here.

You May Also Be Interested In

• Hesai Group (HSAI) Tops Q1 EPS by 8c
• H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)
• H.C. Wainwright Reiterates Neutral Rating on Aethlon Medical (AEMD)